{"product_id":"bmy-business-model-canvas","title":"Bristol-Myers Squibb Company (BMY): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas gives you a clear, research-based view of Bristol-Myers Squibb Company, showing how it builds value through oncology and immunology R\u0026amp;D, clinical trials, licensing, global commercialization, and AI tools, supported by partners such as Microsoft, Anthropic, Hengrui Pharma, and Orbital Therapeutics. You'll see the main growth drivers, including \u003cstrong\u003e$10B\u003c\/strong\u003e annual R\u0026amp;D spend, a late-stage pipeline, a global commercial and manufacturing base, and \u003cstrong\u003eseven $1B+\u003c\/strong\u003e products, along with the key customer segments, hospitals, specialty pharmacies, revenue streams, and cost pressures that shape its specialty medicine strategy.\u003c\/p\u003e\u003ch2\u003eBristol-Myers Squibb Company - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e4\u003c\/strong\u003e named partners appear in this chapter: \u003cstrong\u003e2\u003c\/strong\u003e AI\/data partners and \u003cstrong\u003e2\u003c\/strong\u003e therapeutic partners.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner\u003c\/td\u003e\n\u003ctd\u003eCount\u003c\/td\u003e\n\u003ctd\u003eCanvas function\u003c\/td\u003e\n\u003ctd\u003ePublicly disclosed dollar terms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMicrosoft\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eAI and cloud\u003c\/td\u003e\n\u003ctd\u003eND\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnthropic\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eGenerative AI\u003c\/td\u003e\n\u003ctd\u003eND\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHengrui Pharma\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eDrug licensing and development\u003c\/td\u003e\n\u003ctd\u003eND\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrbital Therapeutics\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eCell therapy development\u003c\/td\u003e\n\u003ctd\u003eND\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003e2\u003c\/strong\u003e partnerships sit on the technology side and \u003cstrong\u003e2\u003c\/strong\u003e sit on the drug-development side.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner group\u003c\/td\u003e\n\u003ctd\u003eNumber of partners\u003c\/td\u003e\n\u003ctd\u003eBusiness Model Canvas role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI \/ data\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eKey Resources, Key Activities\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapeutics \/ licensing\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eKey Activities, Key Partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal named partners\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003eKey Partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eMicrosoft\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e collaboration\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e publicly disclosed dollar terms in this chapter\u003c\/li\u003e\n\u003cli\u003eAI and cloud infrastructure\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAnthropic\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e collaboration\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e publicly disclosed dollar terms in this chapter\u003c\/li\u003e\n\u003cli\u003eGenerative AI\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eHengrui Pharma\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e partnership\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e publicly disclosed dollar terms in this chapter\u003c\/li\u003e\n\u003cli\u003eDrug licensing and development\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrbital Therapeutics\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e partnership\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e publicly disclosed dollar terms in this chapter\u003c\/li\u003e\n\u003cli\u003eCell therapy development\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBristol-Myers Squibb Company - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\u003cp\u003eBristol-Myers Squibb Company's key activities are built around oncology and immunology research, clinical development, deal-making, and global medicine sales. The biggest public dollar signals are the \u003cstrong\u003e$74.0B\u003c\/strong\u003e Celgene acquisition, the \u003cstrong\u003e$13.1B\u003c\/strong\u003e MyoKardia acquisition, the \u003cstrong\u003e$4.1B\u003c\/strong\u003e Turning Point Therapeutics acquisition, the \u003cstrong\u003e$4.8B\u003c\/strong\u003e Mirati Therapeutics acquisition, the \u003cstrong\u003e$14.0B\u003c\/strong\u003e Karuna Therapeutics acquisition, and the \u003cstrong\u003e$4.1B\u003c\/strong\u003e RayzeBio acquisition.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology and immunology R\u0026amp;D.\u003c\/strong\u003e This is the core science engine. Company Name uses internal discovery and outside assets to build its pipeline in cancer, immune disease, and related specialty areas. The scale of this activity shows up in transaction values because Company Name has repeatedly bought late-stage and platform science instead of relying only on internal labs. The largest disclosed examples are the \u003cstrong\u003e$74.0B\u003c\/strong\u003e Celgene transaction, the \u003cstrong\u003e$13.1B\u003c\/strong\u003e MyoKardia transaction, and the \u003cstrong\u003e$4.1B\u003c\/strong\u003e Turning Point Therapeutics transaction. Each number matters because it shows how much capital Company Name is willing to put into future drug candidates before they become commercial products.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$74.0B\u003c\/strong\u003e Celgene added scale in oncology and hematology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$13.1B\u003c\/strong\u003e MyoKardia added cardiovascular science and platform assets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.1B\u003c\/strong\u003e Turning Point Therapeutics added precision oncology assets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical trials and regulatory filings.\u003c\/strong\u003e Company Name turns molecules into medicines through \u003cstrong\u003ePhase 1\u003c\/strong\u003e, \u003cstrong\u003ePhase 2\u003c\/strong\u003e, and \u003cstrong\u003ePhase 3\u003c\/strong\u003e studies, then submits \u003cstrong\u003eNDA\u003c\/strong\u003e, \u003cstrong\u003eBLA\u003c\/strong\u003e, \u003cstrong\u003esNDA\u003c\/strong\u003e, and \u003cstrong\u003esBLA\u003c\/strong\u003e filings. Phase 1 tests safety and dose, Phase 2 looks for early efficacy, and Phase 3 is the confirmatory stage that supports approval decisions. This matters because every approved label extension can add revenue without building a brand-new drug from scratch. The regulatory activity is not optional; it is the gate between research spend and sales.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003ePhase 1\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePhase 2\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePhase 3\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eNDA\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eBLA\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003esNDA\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003esBLA\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eBusiness development transaction\u003c\/strong\u003e\u003c\/td\u003e\n \u003ctd\u003e\u003cstrong\u003eAmount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eStrategic role\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCelgene\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$74.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOncology and hematology scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyoKardia\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.1B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCardiovascular science platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTurning Point Therapeutics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.1B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrecision oncology pipeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMirati Therapeutics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eKRAS-focused oncology assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKaruna Therapeutics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNeuroscience assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRayzeBio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.1B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRadiopharmaceutical capabilities\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eBusiness development and licensing.\u003c\/strong\u003e Company Name uses acquisitions and licensing-style structures to buy time, pipeline depth, and technical capability. The table above shows the financial shape of that strategy: \u003cstrong\u003e$14.0B\u003c\/strong\u003e for Karuna, \u003cstrong\u003e$4.1B\u003c\/strong\u003e for RayzeBio, and \u003cstrong\u003e$4.8B\u003c\/strong\u003e for Mirati show a steady willingness to pay for late-stage and differentiated assets. This matters because external deals reduce dependence on a single discovery path and help fill future revenue gaps when older products lose exclusivity.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$14.0B\u003c\/strong\u003e shows willingness to buy neuroscience assets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.1B\u003c\/strong\u003e shows willingness to buy radiopharmaceutical assets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.8B\u003c\/strong\u003e shows willingness to buy targeted oncology assets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal commercialization of medicines.\u003c\/strong\u003e This is the part of the model that converts approvals into cash flow. The latest full-year public revenue figure available in Company Name's reporting is \u003cstrong\u003e$45.0B\u003c\/strong\u003e for 2023. That number matters because commercialization funds the next round of research, trials, and acquisitions. Global commercialization includes pricing, market access, medical affairs, sales execution, supply chain management, and lifecycle management across the United States and international markets.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eU.S. launch execution\u003c\/li\u003e\n\u003cli\u003eInternational launch execution\u003c\/li\u003e\n\u003cli\u003ePayer access and reimbursement\u003c\/li\u003e\n\u003cli\u003eSupply and distribution\u003c\/li\u003e\n\u003cli\u003eLifecycle management\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI tool deployment.\u003c\/strong\u003e Company Name does not disclose a separate AI revenue line, AI segment, or standalone AI budget in public financial reporting, so the publicly disclosed amount is \u003cstrong\u003e$0\u003c\/strong\u003e for those items. AI therefore sits inside internal discovery, trial operations, and commercial workflows rather than as a reported business line.\u003c\/p\u003e\n\u003ch2\u003eBristol-Myers Squibb Company - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e7\u003c\/strong\u003e products above \u003cstrong\u003e$1B\u003c\/strong\u003e, \u003cstrong\u003e$10B+\u003c\/strong\u003e annual R\u0026amp;D spend, and \u003cstrong\u003e$48.3B\u003c\/strong\u003e in 2024 revenue define Bristol-Myers Squibb Company's key resources.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eNumeric marker\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth portfolio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBreyanzi, Reblozyl, Camzyos, Cobenfy, Opdualag, Sotyktu\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage pipeline\u003c\/td\u003e\n\u003ctd\u003ePhase 3\u003c\/td\u003e\n\u003ctd\u003eLate-stage development programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual R\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10B+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch and development spending\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal commercial and manufacturing base\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$48.3B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 total revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeven $1B+ products\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEliquis, Opdivo, Revlimid, Orencia, Pomalyst\/Imnovid, Reblozyl, Breyanzi\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eGrowth portfolio: Breyanzi, Reblozyl, Camzyos, Cobenfy, Opdualag, Sotyktu.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e7\u003c\/strong\u003e products above \u003cstrong\u003e$1B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eEliquis\u003c\/li\u003e\n\u003cli\u003eOpdivo\u003c\/li\u003e\n\u003cli\u003eRevlimid\u003c\/li\u003e\n\u003cli\u003eOrencia\u003c\/li\u003e\n\u003cli\u003ePomalyst\/Imnovid\u003c\/li\u003e\n\u003cli\u003eReblozyl\u003c\/li\u003e\n\u003cli\u003eBreyanzi\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLate-stage pipeline: Phase 3.\u003c\/p\u003e\n\n\u003cp\u003eAnnual R\u0026amp;D spend: \u003cstrong\u003e$10B+\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eGlobal commercial and manufacturing base: \u003cstrong\u003e$48.3B\u003c\/strong\u003e.\u003c\/p\u003e\u003ch2\u003eBristol-Myers Squibb Company - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\u003cp\u003eBristol-Myers Squibb Company's value proposition is built on specialty medicines with large, durable revenue streams. In 2023, Bristol-Myers Squibb Company reported \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in revenue, and Eliquis generated \u003cstrong\u003e$12.2 billion\u003c\/strong\u003e in net product sales, equal to \u003cstrong\u003e27.1%\u003c\/strong\u003e of that total.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInnovative specialty medicines\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBristol-Myers Squibb Company sells prescription drugs for complex diseases that need specialist diagnosis, long treatment cycles, and strong reimbursement support. That matters because specialty medicines are not bought like low-cost primary care drugs. They depend on clinical evidence, physician adoption, payer coverage, and specialty pharmacy distribution. The company's scale gives it room to fund trials, manufacturing, and market access work at a level smaller biotech firms usually cannot match. The commercial model is concentrated, but the revenue per product can be very large when the medicine becomes a standard treatment in its category.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBroad oncology portfolio\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOncology is the biggest part of the company's value proposition. The portfolio includes Opdivo, Yervoy, Revlimid, Pomalyst, Abecma, Breyanzi, and Reblozyl. These products cover checkpoint inhibition, immunomodulation, cell therapy, and hematology-oncology. The 2019 Celgene acquisition for \u003cstrong\u003e$74.0 billion\u003c\/strong\u003e was central to building this base. That transaction expanded the company's cancer and blood disorder reach and made oncology more than a single-product story. In business model terms, that reduces dependence on any one drug, while keeping the company positioned in one of the highest-value parts of medicine.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eValue proposition element\u003c\/th\u003e\n\u003cth\u003eReal-life number or amount\u003c\/th\u003e\n\u003cth\u003eBusiness meaning\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in 2023\u003c\/td\u003e\n\u003ctd\u003eScale for specialty R\u0026amp;D, manufacturing, and access support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis net product sales\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$12.2 billion\u003c\/strong\u003e in 2023\u003c\/td\u003e\n\u003ctd\u003eShows cardiovascular franchise strength and payer acceptance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis share of revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e27.1%\u003c\/strong\u003e of $45.0 billion\u003c\/td\u003e\n\u003ctd\u003eShows how much one brand can support the business model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCelgene acquisition\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$74.0 billion\u003c\/strong\u003e in 2019\u003c\/td\u003e\n\u003ctd\u003eExpanded oncology and hematology depth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKaruna Therapeutics acquisition\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$14.0 billion\u003c\/strong\u003e in 2024\u003c\/td\u003e\n\u003ctd\u003eAdded neuroscience pipeline assets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRayzeBio acquisition\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.1 billion\u003c\/strong\u003e in 2024\u003c\/td\u003e\n\u003ctd\u003eAdded radiopharmaceutical capability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCardiovascular and immunology therapies\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe cardiovascular and immunology franchises make the company less dependent on oncology. Eliquis is the clearest example, with \u003cstrong\u003e$12.2 billion\u003c\/strong\u003e in 2023 sales. Other products in this part of the portfolio include Camzyos, Orencia, Sotyktu, and Zeposia. This matters because it broadens relationships across cardiology, rheumatology, dermatology, neurology, and gastroenterology. It also spreads risk across different disease areas and prescriber groups. When one area slows, another can still support revenue and keep the company's specialty sales base stable.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNew indications and pipeline expansion\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBristol-Myers Squibb Company uses label expansion and pipeline deals to keep existing medicines relevant and add new platforms. New indications can extend the commercial life of a drug without building a brand from zero. The company's recent deal activity shows that strategy clearly. Karuna Therapeutics added neuroscience exposure for \u003cstrong\u003e$14.0 billion\u003c\/strong\u003e. RayzeBio added radiopharmaceutical capability for \u003cstrong\u003e$4.1 billion\u003c\/strong\u003e. These moves matter because they expand the company beyond mature franchises and into areas where new clinical data can create more revenue over time.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eTherapy area\u003c\/th\u003e\n\u003cth\u003eFirst FDA approval year\u003c\/th\u003e\n\u003cth\u003eRole in value proposition\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYervoy\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e2011\u003c\/td\u003e\n\u003ctd\u003eCheckpoint inhibitor franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis\u003c\/td\u003e\n\u003ctd\u003eCardiovascular\u003c\/td\u003e\n\u003ctd\u003e2012\u003c\/td\u003e\n\u003ctd\u003eCore anticoagulant franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpdivo\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e2014\u003c\/td\u003e\n\u003ctd\u003eMajor immuno-oncology franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReblozyl\u003c\/td\u003e\n\u003ctd\u003eHematology\u003c\/td\u003e\n\u003ctd\u003e2019\u003c\/td\u003e\n\u003ctd\u003eAnemia treatment in blood disorders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZeposia\u003c\/td\u003e\n\u003ctd\u003eImmunology\u003c\/td\u003e\n\u003ctd\u003e2020\u003c\/td\u003e\n\u003ctd\u003eMultiple immune-mediated disease uses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbecma\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003ctd\u003eCell therapy franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreyanzi\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003ctd\u003eCell therapy franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCamzyos\u003c\/td\u003e\n\u003ctd\u003eCardiovascular\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003eHypertrophic cardiomyopathy franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSotyktu\u003c\/td\u003e\n\u003ctd\u003eImmunology\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003ctd\u003eOral immunology franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrencia\u003c\/td\u003e\n\u003ctd\u003eImmunology\u003c\/td\u003e\n\u003ctd\u003e2005\u003c\/td\u003e\n\u003ctd\u003eEstablished inflammatory disease franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAccess expansion via ASPIRE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAccess is part of the value proposition because specialty medicines only matter if patients can start and stay on treatment. That makes reimbursement, prior authorization, specialty pharmacy routing, and patient support part of the commercial model. ASPIRE fits that role by focusing on access expansion around specialty care. This is especially important in oncology and chronic disease settings, where treatment delays can reduce both clinical impact and prescription conversion. With \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in 2023 revenue, Bristol-Myers Squibb Company has the scale to support access programs that help prescriptions turn into actual treatment.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSpecialist diagnosis\u003c\/li\u003e\n\u003cli\u003eBiomarker testing\u003c\/li\u003e\n\u003cli\u003ePrior authorization\u003c\/li\u003e\n\u003cli\u003eSpecialty pharmacy distribution\u003c\/li\u003e\n\u003cli\u003eInfusion or hospital administration\u003c\/li\u003e\n\u003cli\u003ePatient navigation and reimbursement support\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBristol-Myers Squibb Company - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003eBristol-Myers Squibb Company's customer relationships are built around \u003cstrong\u003e$48.3B\u003c\/strong\u003e in 2024 revenue and approximately \u003cstrong\u003e34,100\u003c\/strong\u003e employees, because its medicines depend on repeat interaction with physicians, hospitals, payers, and patients.\u003c\/p\u003e\n\n\u003cp\u003eLong-term provider relationships\u003c\/p\u003e\n\u003cp\u003eThe provider base is built around specialty prescribing, hospital use, and account-level access. That matters because treatment decisions for oncology, hematology, immunology, cardiovascular disease, and neuroscience are often made by specialists rather than retail channels. The company's relationship model has to stay active across diagnosis, prescribing, reimbursement, administration, and follow-up, which is why commercial teams, medical teams, and reimbursement staff all sit inside the same customer loop.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$48.3B\u003c\/strong\u003e 2024 revenue supports broad field coverage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e34,100\u003c\/strong\u003e employees support commercial, medical, and operational contact points.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e cell therapies, Breyanzi and Abecma, require treatment-center coordination.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMedical and regulatory support\u003c\/p\u003e\n\u003cp\u003eMedical and regulatory support is part of the relationship because specialty drugs need label-compliant education, safety monitoring, and post-approval communication. For drugs that need safety monitoring, label updates, and treatment-center coordination, the medical relationship is as important as the sales relationship. In \u003cstrong\u003e2024\u003c\/strong\u003e, Bristol-Myers Squibb Company added Cobenfy, which expanded prescriber education into psychiatry.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e FDA approval for Cobenfy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e cell therapies in the marketed portfolio.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$48.3B\u003c\/strong\u003e in 2024 revenue provides the base for medical affairs and compliance systems.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatient access programs\u003c\/p\u003e\n\u003cp\u003ePatient access is central because specialty medicines often face reimbursement checks before a patient starts therapy. The relationship work sits around eligibility, coverage, and continuity, not just the prescription date. Prior authorization, specialty pharmacy routing, and financial support all affect whether a patient gets from prescription to first fill.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eAccess point\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003cth\u003eCustomer relationship role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$48.3B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports access and support infrastructure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal workforce\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e34,100\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports patient service and provider contact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell therapies\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRequires treatment-site and patient coordination\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePsychiatry launch\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpands onboarding and support needs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eGlobal pharma collaboration\u003c\/p\u003e\n\u003cp\u003eCollaboration extends the relationship model beyond direct customers. The clearest example is the Pfizer partnership on Eliquis, which shares development, market access, and support work across two large pharmaceutical companies. That kind of relationship matters because it spreads risk, extends reach, and keeps the product tied to both prescribers and payers in multiple markets.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e major co-commercialization partnership with Pfizer on Eliquis.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e cell therapies that depend on external treatment networks.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e remains the latest full-year revenue base at \u003cstrong\u003e$48.3B\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBristol-Myers Squibb Company - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003eBristol-Myers Squibb Company's channel model has 4 access paths: hospitals and clinics, specialty pharmacies, a global sales force, and regulatory and reimbursement pathways. The mix matters because the company reported \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in 2023 net sales, and those sales depend on whether a therapy is given in a treatment center, filled by a pharmacy, or covered by a payer.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eChannel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life access pattern\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eExample products\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eChannel impact\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals and clinics\u003c\/td\u003e\n\u003ctd\u003e1-time cell therapy infusion; recurring infusion schedules such as every \u003cstrong\u003e3\u003c\/strong\u003e weeks\u003c\/td\u003e\n\u003ctd\u003eBreyanzi, Abecma, Reblozyl, Opdivo\u003c\/td\u003e\n\u003ctd\u003eMedical benefit billing, buy-and-bill, site-of-care control\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e times daily, \u003cstrong\u003e1\u003c\/strong\u003e time daily, and long-term refill cycles\u003c\/td\u003e\n\u003ctd\u003eEliquis, Sotyktu, Camzyos, Zeposia\u003c\/td\u003e\n\u003ctd\u003ePharmacy benefit coverage, refill management, prior authorization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal sales force\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e major customer layers: prescribers, hospital pharmacists, payer teams, and pathway committees\u003c\/td\u003e\n\u003ctd\u003eOncology, hematology, cardiovascular, and immunology brands\u003c\/td\u003e\n\u003ctd\u003eClinical education, formulary access, prescribing support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory and reimbursement pathways\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e access gates: approval and coverage\u003c\/td\u003e\n\u003ctd\u003eFDA, EMA, Medicare Part B, Medicare Part D, Medicaid, commercial plans\u003c\/td\u003e\n\u003ctd\u003eTurns clinical demand into paid volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospitals and clinics\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHospitals and clinics are the main channel for provider-administered therapies. This matters for products that need infusion, close monitoring, or specialized handling. Breyanzi and Abecma are given as 1-time cell therapy infusions, while Reblozyl follows a recurring schedule such as every \u003cstrong\u003e3\u003c\/strong\u003e weeks. In this channel, the hospital or clinic often buys the drug first and then bills the payer after administration. That is the buy-and-bill model. For you, the key point is that channel control sits with the treatment site, not the patient, so access depends on hospital stocking, staff capacity, prior authorization, and payer rules tied to the medical benefit.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e1-time infusion therapies push demand through tertiary centers and infusion units.\u003c\/li\u003e\n\u003cli\u003eRecurring infusions create repeated billing events and repeat site-of-care decisions.\u003c\/li\u003e\n\u003cli\u003eHospital access is especially important for oncology and cell therapy products.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialty pharmacies\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSpecialty pharmacies are the main channel for many oral therapies and long-duration treatments. Eliquis is taken \u003cstrong\u003e2\u003c\/strong\u003e times daily, while Sotyktu, Camzyos, and Zeposia are once-daily therapies. This channel matters because the pharmacy benefit is different from the medical benefit: the patient fills the medicine through a pharmacy instead of receiving it in a clinic. Specialty pharmacies also handle benefit verification, refill timing, and adherence support. For Bristol-Myers Squibb Company, this channel is important for products that depend on chronic use, repeated refills, and low abandonment rates.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eEliquis: \u003cstrong\u003e2\u003c\/strong\u003e times daily.\u003c\/li\u003e\n\u003cli\u003eSotyktu: \u003cstrong\u003e1\u003c\/strong\u003e time daily.\u003c\/li\u003e\n\u003cli\u003eCamzyos: \u003cstrong\u003e1\u003c\/strong\u003e time daily.\u003c\/li\u003e\n\u003cli\u003eZeposia: \u003cstrong\u003e1\u003c\/strong\u003e time daily.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal sales force\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe global sales force is the human channel that connects Bristol-Myers Squibb Company with physicians, hospital systems, and payer decision makers. It matters because prescriptions are written by clinicians, not by end customers. The field model supports 4 main customer groups in practice: oncologists, hematologists, cardiologists, and rheumatology or dermatology prescribers. The sales force does not replace the pharmacy or the hospital; it helps drive diagnosis, prescribing, pathway inclusion, and formulary placement. In academic work, this channel is useful because it shows how a pharmaceutical company creates demand before a prescription is filled.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003ePhysician education supports brand adoption after approval.\u003c\/li\u003e\n\u003cli\u003eHospital account teams help with pathway and formulary access.\u003c\/li\u003e\n\u003cli\u003ePayer-facing teams help align clinical data with coverage rules.\u003c\/li\u003e\n\u003cli\u003eField coverage is most valuable for complex specialty drugs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory and reimbursement pathways\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRegulatory and reimbursement pathways are a channel gate, not just a legal step. Bristol-Myers Squibb Company needs 2 approvals in practice before a drug creates steady sales: regulatory approval and payer coverage. In the U.S., that usually means FDA approval first, then reimbursement through Medicare Part B, Medicare Part D, Medicaid, or commercial plans. Outside the U.S., the company must work through EMA review and country-by-country payment decisions. This channel matters because clinical demand does not turn into revenue unless the medicine is approved, covered, and paid for. A therapy can have strong physician interest and still have weak sales if coverage is delayed.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eFDA approval opens the U.S. market.\u003c\/li\u003e\n\u003cli\u003eMedicare Part B usually matters for provider-administered drugs.\u003c\/li\u003e\n\u003cli\u003eMedicare Part D usually matters for pharmacy-dispensed drugs.\u003c\/li\u003e\n\u003cli\u003eEMA review and national reimbursement decisions shape ex-U.S. access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eBristol-Myers Squibb Company - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$48.3B\u003c\/strong\u003e in 2024 revenue depends on five quantified customer groups: oncology patients, cardiovascular patients, immunology patients, hematology patients, and the healthcare provider and payer layer. The largest measurable disease pools tied to Company Name are \u003cstrong\u003e20.0 million\u003c\/strong\u003e new cancer cases in 2022, \u003cstrong\u003e17.9 million\u003c\/strong\u003e cardiovascular deaths each year, and \u003cstrong\u003e18 million\u003c\/strong\u003e people living with rheumatoid arthritis globally.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer segment\u003c\/td\u003e\n\u003ctd\u003eReal-life demand numbers\u003c\/td\u003e\n\u003ctd\u003eClinical buying channel\u003c\/td\u003e\n\u003ctd\u003eCommercial relevance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20.0 million\u003c\/strong\u003e new cases worldwide in 2022; \u003cstrong\u003e9.7 million\u003c\/strong\u003e deaths worldwide in 2022; \u003cstrong\u003e2,001,140\u003c\/strong\u003e new U.S. cases in 2024; \u003cstrong\u003e611,720\u003c\/strong\u003e U.S. deaths in 2024\u003c\/td\u003e\n\u003ctd\u003eOncologists, hospitals, infusion centers, specialty pharmacies\u003c\/td\u003e\n\u003ctd\u003eMulti-line treatment, repeated dosing, and high payer scrutiny\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiovascular patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17.9 million\u003c\/strong\u003e cardiovascular deaths annually; about \u003cstrong\u003e33.5 million\u003c\/strong\u003e people worldwide with atrial fibrillation\u003c\/td\u003e\n\u003ctd\u003eCardiologists, primary care physicians, hospital discharge teams\u003c\/td\u003e\n\u003ctd\u003eLong-term anticoagulation and chronic refill dependence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunology patients\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e18 million\u003c\/strong\u003e people worldwide with rheumatoid arthritis; about \u003cstrong\u003e1.5 million\u003c\/strong\u003e adults in the United States with rheumatoid arthritis\u003c\/td\u003e\n\u003ctd\u003eRheumatologists, outpatient clinics, specialty pharmacies\u003c\/td\u003e\n\u003ctd\u003eRecurring prescriptions, monitoring, and renewal-based access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHematology patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e35,780\u003c\/strong\u003e new U.S. multiple myeloma cases in 2024; \u003cstrong\u003e12,540\u003c\/strong\u003e U.S. deaths in 2024\u003c\/td\u003e\n\u003ctd\u003eHematologists, transplant centers, academic cancer centers, infusion sites\u003c\/td\u003e\n\u003ctd\u003eSpecialty care concentration and high-value treatment pathways\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare providers and payers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,001,140\u003c\/strong\u003e U.S. cancer cases in 2024; \u003cstrong\u003e35,780\u003c\/strong\u003e U.S. multiple myeloma cases in 2024; \u003cstrong\u003e1.5 million\u003c\/strong\u003e U.S. rheumatoid arthritis patients; \u003cstrong\u003e33.5 million\u003c\/strong\u003e people worldwide with atrial fibrillation; \u003cstrong\u003e$48.3B\u003c\/strong\u003e 2024 revenue base\u003c\/td\u003e\n\u003ctd\u003eFormulary committees, pharmacy benefit managers, insurers, hospitals, integrated delivery networks\u003c\/td\u003e\n\u003ctd\u003ePrior authorization, formulary status, and site-of-care rules decide access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOncology patients\u003c\/strong\u003e are the largest measurable demand pool, with \u003cstrong\u003e20.0 million\u003c\/strong\u003e new cases and \u003cstrong\u003e9.7 million\u003c\/strong\u003e deaths worldwide in 2022, plus \u003cstrong\u003e2,001,140\u003c\/strong\u003e new U.S. cases and \u003cstrong\u003e611,720\u003c\/strong\u003e U.S. deaths in 2024. This segment includes solid tumors and blood cancers, so treatment depth matters more than volume alone. The patient pool is large enough to support broad clinical trial activity, repeated treatment lines, and high access pressure from payers.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e20.0 million\u003c\/strong\u003e worldwide new cancer cases in 2022\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e9.7 million\u003c\/strong\u003e worldwide cancer deaths in 2022\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2,001,140\u003c\/strong\u003e U.S. new cancer cases in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e611,720\u003c\/strong\u003e U.S. cancer deaths in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCardiovascular patients\u003c\/strong\u003e are a chronic-use segment, with \u003cstrong\u003e17.9 million\u003c\/strong\u003e cardiovascular deaths globally each year and about \u003cstrong\u003e33.5 million\u003c\/strong\u003e people worldwide living with atrial fibrillation. That size matters because long-term use creates repeated pharmacy claims, refill management, and payer dependence. For Company Name, this segment is tied to chronic therapy rather than a one-time intervention, so access continuity is central to revenue durability.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e17.9 million\u003c\/strong\u003e cardiovascular deaths annually\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e33.5 million\u003c\/strong\u003e people worldwide with atrial fibrillation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImmunology patients\u003c\/strong\u003e are smaller than oncology in mortality terms but important in recurring prescriptions. Rheumatoid arthritis affects about \u003cstrong\u003e18 million\u003c\/strong\u003e people worldwide and about \u003cstrong\u003e1.5 million\u003c\/strong\u003e adults in the United States. These patients often stay on therapy for long periods, so adherence, safety monitoring, and payer renewal decisions matter more than a single start date. This segment rewards therapies that can hold access across multiple refill cycles.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e18 million\u003c\/strong\u003e people worldwide with rheumatoid arthritis\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1.5 million\u003c\/strong\u003e U.S. adults with rheumatoid arthritis\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eHematology patients\u003c\/strong\u003e are a high-value specialty segment. Multiple myeloma accounted for \u003cstrong\u003e35,780\u003c\/strong\u003e new U.S. cases in 2024 and \u003cstrong\u003e12,540\u003c\/strong\u003e U.S. deaths in 2024. The treatment path often runs through academic centers, transplant centers, and infusion sites, so access is shaped by physician choice and payer rules. Smaller patient counts can still produce meaningful commercial value because treatment intensity and specialty care use are high.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e35,780\u003c\/strong\u003e new U.S. multiple myeloma cases in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e12,540\u003c\/strong\u003e U.S. multiple myeloma deaths in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eHealthcare providers and payers\u003c\/strong\u003e are the access layer for all of these patients. They decide formulary status, prior authorization, site of care, and step therapy, so they influence whether the same \u003cstrong\u003e2,001,140\u003c\/strong\u003e U.S. cancer cases, \u003cstrong\u003e35,780\u003c\/strong\u003e U.S. multiple myeloma cases, \u003cstrong\u003e1.5 million\u003c\/strong\u003e U.S. rheumatoid arthritis patients, and \u003cstrong\u003e33.5 million\u003c\/strong\u003e people with atrial fibrillation worldwide can reach treatment. That is why payer access and provider adoption matter across BMS's \u003cstrong\u003e$48.3B\u003c\/strong\u003e 2024 revenue base.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2,001,140\u003c\/strong\u003e U.S. cancer cases in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e35,780\u003c\/strong\u003e U.S. multiple myeloma cases in 2024\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1.5 million\u003c\/strong\u003e U.S. rheumatoid arthritis patients\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e33.5 million\u003c\/strong\u003e people worldwide with atrial fibrillation\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBristol-Myers Squibb Company - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eR\u0026amp;D spending\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 research and development expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 acquired in-process research and development expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 combined R\u0026amp;D-related expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.3B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing and supply chain\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 cost of products sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 gross profit after cost of products sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$37.3B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eBusiness development deals\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eKaruna Therapeutics acquisition value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKaruna Therapeutics consideration per share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$330.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRayzeBio acquisition value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.1B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRayzeBio consideration per share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$62.50\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMirati Therapeutics acquisition value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMirati Therapeutics consideration per share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRestructuring and layoffs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2,200\u003c\/strong\u003e positions\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.5B\u003c\/strong\u003e expected annual savings\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2025\u003c\/strong\u003e target for completion\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLitigation and compliance\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 selling, general and administrative expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.2B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 legal and compliance proxy cost bucket\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.2B\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003ch2\u003eBristol-Myers Squibb Company - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e total revenues in 2023, driven by prescription drug sales.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRevenue stream\u003c\/th\u003e\n\u003cth\u003eReal-life amounts\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription drug sales\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e total revenues in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth portfolio revenue\u003c\/td\u003e\n\u003ctd\u003eEliquis \u003cstrong\u003e$11.5 billion\u003c\/strong\u003e, Opdivo \u003cstrong\u003e$9.3 billion\u003c\/strong\u003e, Orencia \u003cstrong\u003e$3.1 billion\u003c\/strong\u003e, Yervoy \u003cstrong\u003e$2.6 billion\u003c\/strong\u003e, Zeposia \u003cstrong\u003e$0.8 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy portfolio revenue\u003c\/td\u003e\n\u003ctd\u003eRevlimid \u003cstrong\u003e$5.4 billion\u003c\/strong\u003e, Pomalyst\/Imnovid \u003cstrong\u003e$3.2 billion\u003c\/strong\u003e, Abraxane \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e, Sprycel \u003cstrong\u003e$0.5 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNewly approved product sales\u003c\/td\u003e\n\u003ctd\u003eReblozyl \u003cstrong\u003e$1.2 billion\u003c\/strong\u003e, Breyanzi \u003cstrong\u003e$0.6 billion\u003c\/strong\u003e, Camzyos \u003cstrong\u003e$0.4 billion\u003c\/strong\u003e, Opdualag \u003cstrong\u003e$0.4 billion\u003c\/strong\u003e, Sotyktu \u003cstrong\u003e$0.2 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational product sales\u003c\/td\u003e\n\u003ctd\u003eEliquis \u003cstrong\u003e$4.4 billion\u003c\/strong\u003e, Opdivo \u003cstrong\u003e$2.9 billion\u003c\/strong\u003e, Revlimid \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e, Pomalyst\/Imnovid \u003cstrong\u003e$1.9 billion\u003c\/strong\u003e, Orencia \u003cstrong\u003e$0.9 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePrescription drug sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEliquis \u003cstrong\u003e$11.5 billion\u003c\/strong\u003e; Opdivo \u003cstrong\u003e$9.3 billion\u003c\/strong\u003e; Revlimid \u003cstrong\u003e$5.4 billion\u003c\/strong\u003e; Pomalyst\/Imnovid \u003cstrong\u003e$3.2 billion\u003c\/strong\u003e; Orencia \u003cstrong\u003e$3.1 billion\u003c\/strong\u003e; Yervoy \u003cstrong\u003e$2.6 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGrowth portfolio revenue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEliquis: \u003cstrong\u003e$11.5 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOpdivo: \u003cstrong\u003e$9.3 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOrencia: \u003cstrong\u003e$3.1 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eYervoy: \u003cstrong\u003e$2.6 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eZeposia: \u003cstrong\u003e$0.8 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLegacy portfolio revenue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevlimid: \u003cstrong\u003e$5.4 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePomalyst\/Imnovid: \u003cstrong\u003e$3.2 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAbraxane: \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eSprycel: \u003cstrong\u003e$0.5 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eNewly approved product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReblozyl: \u003cstrong\u003e$1.2 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eBreyanzi: \u003cstrong\u003e$0.6 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCamzyos: \u003cstrong\u003e$0.4 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOpdualag: \u003cstrong\u003e$0.4 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eSotyktu: \u003cstrong\u003e$0.2 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInternational product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEliquis outside the U.S.: \u003cstrong\u003e$4.4 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOpdivo outside the U.S.: \u003cstrong\u003e$2.9 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eRevlimid outside the U.S.: \u003cstrong\u003e$2.4 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePomalyst\/Imnovid outside the U.S.: \u003cstrong\u003e$1.9 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOrencia outside the U.S.: \u003cstrong\u003e$0.9 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601587138709,"sku":"bmy-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/bmy-business-model-canvas.png?v=1740155287","url":"https:\/\/dcf-model.com\/products\/bmy-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}